Dr Reddy’s Labs launches desmopressin acetate injection in US market

Dr Reddy’s Laboratories announced the launch of the US Food and Drug Administration (FDA) approved desmopressin acetate injection USP, 4 mcg/mL single-dose ampules, a therapeutic equivalent generic version of DDAVP (desmopressin acetate) injection, 4 mcg/mL.

Dr. Reddy’s desmopressin acetate injection USP, 4 mcg/mL is available in a carton of ten 1 mL single dose ampules.

Marc Kikuchi, CEO, North America Generics, Dr Reddy’s Laboratories, commented, “The launch of desmopressin injection demonstrates a strong, growing collaboration with SunGen Pharma. We look forward to future opportunities with this company.”

Isaac Liu, Ph.D., Co-CEO of SunGen, stated, “We are pleased to be working with Dr. Reddy’s for this launch. The launch of desmopressin demonstrates our strong development capabilities. We look forward to collaborating further to bring specialty pharmaceutical drugs to the markets around the world.”

The desmopressin acetate injection USP brand and generic market had US sales of approximately $20.9 million MAT for the most recent twelve months ending in March 2020, according to IQVIA Health.

PHARMALEADERS

Pharmaleaders is India’s first opinion based & research driven bi-monthly magazine & has a decade of relentless reporting in Pharma Journalism in an unbiased, fearless & independent way. Over the last one decade, The Magazine has covered some of the biggest voices in the healthcare Industry. Available both in digital & printed format, Pharmaleaders has emerged out as a leading title in voicing the opinion of the healthcare industry.